Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rice swap shows promise for prediabetes

NCT ID NCT07298304

Disease control Sponsor: Dr. Soetomo General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether eating sorghum rice instead of white rice for one week could improve health in people with prediabetes. Twenty-six police officers with prediabetes took part. Half ate sorghum rice, and half ate white rice. The researchers measured changes in a hormone called leptin, which is linked to appetite and blood sugar control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

Mar 2022

Finished

Mar 2023

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 58 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 58 years * Diagnosed with prediabetes which met one of the criteria per PERKENI 2021 as follow: * Fasting plasma glucose 100-125 mg/dL * 2-hour postprandial glucose 140-199 mg/dL * HbA1c 5.7-6.4% * Willing to comply with dietary monitoring and lifestyle instructions * Active duty police officers Exclusion Criteria: * Pregnancy * History of malignancy * Diagnosed diabetes mellitus * Acute infection * Severe hepatic or renal impairment * Current use of medication such as: glucose-lowering, corticosteroid, or anti-obesity medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glucose intolerance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glucose intolerance Insulin Resistance Obesity obesity disorder Overweight prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glucose intolerance Insulin resistance Obesity and overweight Prediabetic state

Contacts and locations

Locations

  • Soetomo General Hospital

    Surabaya, East Java, 60241, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.